| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Actavis has been one of the most acquisitive in the generic field in recent
years, buying a large number of manufacturers and distributors. This report
provides an insight into the company, reviewing its current business structure
and activities.
Actavis, originally named Pharmaco, was created in 1956; in May 2004 it
changed its name to Actavis. The company is headquartered in Iceland, but has
operations in over 25 countries. Actavis has manufacturing and development
facilities in Bulgaria, Turkey, Malta, Iceland and Serbia, and employs over
7,000 members of staff.
The company is also particularly active in the non-EU parts of Europe, such as
Bulgaria, Russia, and Serbia, but in recent years has been pushing for a
stronger presence in the EU, and in the United States. The company gained its
first US ANDA approvals in August 2005, through its Amide subsidiary.
The company has been one of the most acquisitive in the generic field in
recent years, buying a large number of manufacturers and distributors. The
most significant was announced in October 2005, when Actavis revealed the
US$810 million purchase of Alpharma's human generics businesses. The deal will
give Actavis a major presence in the US market and turn the company into one
of the world's top five generic manufacturers. The acquisition was closed in
December 2005. Other major recent acquisitions include Amide Pharmaceuticals
(USA) and Fako (Turkey).
With the Alpharma purchase, Actavis estimates 2006 revenues of 1.3 billion
euros in 2006, with an EBITDA of 19-20%. Combined revenues for Actavis and
Alpharma's human generics business amounted to just under 1.2 billion euros in
2004.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS
- Own Brand Products
- Leading Own Brand Products, 2004 (Euro millions)
- Third Party Products
- Amide Pharmaceutical
- Amide Pharmaceuticals, ANDA Approvals 2002-05
- Recent product approvals
- Amide gains cyclobenzaprine approval
- Isotretinoin launched in UAE and Iran
- Actavis launches ramipril in France
- Lansoprazole
- Lamotrigine launched in the Czech Rep
- Glimepiride and benazepril
- Amide gains hydromorphone and dantrolene approvals
- Actavis launches sertraline in 14 European countries
- Ramipril launched in Hungary
- Actavis launches cetirizine in Russia
- Terbinafine
- Amide receives FDA approval for mirtazapine ODT
- Fosinopril
- Benazepril+HCTZ
- Lamotrigine
- FINANCIAL RESULTS
- MAJOR DEVELOPMENTS
- Actavis building new R&D centre in Ic
- Mergers, acquisitions and agreements
- Pliva
- Actavis to acquire Alpharma's Human Generics business
- Pro forma revenues for Actavis/Alpharma, 2004 & H1 2005 (million euros)
- Fako
- Actavis acquires Denmark's Ophtha
- Actavis acquires Kéri Pharma Generics.
- Actavis agrees to acquire Higia
- Actavis sells Bulgarian API plant, retains dosage form capacity
- Actavis acquires Amide Pharmaceutical
- Acquisition of Pharma Avalanche
- Actavis expands presence in India
- Actavis acquires Biovena
- CONTACT DETAILS
|
